AU2023214481A1 - Gjb2 regulatory elements and uses thereof - Google Patents

Gjb2 regulatory elements and uses thereof Download PDF

Info

Publication number
AU2023214481A1
AU2023214481A1 AU2023214481A AU2023214481A AU2023214481A1 AU 2023214481 A1 AU2023214481 A1 AU 2023214481A1 AU 2023214481 A AU2023214481 A AU 2023214481A AU 2023214481 A AU2023214481 A AU 2023214481A AU 2023214481 A1 AU2023214481 A1 AU 2023214481A1
Authority
AU
Australia
Prior art keywords
seq
gjb2
polynucleotide
sequence identity
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023214481A
Other languages
English (en)
Inventor
Joseph Burns
Sarah CANCELARICH
Daniela DI BATTISTA MIANI
Meghan DRUMMOND SAMUELSON
Kathryn ELLIS
Tyler Gibson
Kevin LEBO
Gabriela PREGERNIG
Leah SABIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Decibel Therapeutics Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc, Decibel Therapeutics Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2023214481A1 publication Critical patent/AU2023214481A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023214481A 2022-02-04 2023-02-03 Gjb2 regulatory elements and uses thereof Pending AU2023214481A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263306941P 2022-02-04 2022-02-04
US202263306928P 2022-02-04 2022-02-04
US63/306,941 2022-02-04
US63/306,928 2022-02-04
PCT/US2023/061953 WO2023150689A2 (en) 2022-02-04 2023-02-03 Gjb2 regulatory elements and uses thereof

Publications (1)

Publication Number Publication Date
AU2023214481A1 true AU2023214481A1 (en) 2024-08-08

Family

ID=87552983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023214481A Pending AU2023214481A1 (en) 2022-02-04 2023-02-03 Gjb2 regulatory elements and uses thereof

Country Status (11)

Country Link
US (1) US20250127928A1 (cg-RX-API-DMAC10.html)
EP (1) EP4473005A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506419A (cg-RX-API-DMAC10.html)
KR (1) KR20240156606A (cg-RX-API-DMAC10.html)
AU (1) AU2023214481A1 (cg-RX-API-DMAC10.html)
CA (1) CA3250345A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002306A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024012057A2 (cg-RX-API-DMAC10.html)
IL (1) IL314705A (cg-RX-API-DMAC10.html)
MX (1) MX2024009520A (cg-RX-API-DMAC10.html)
WO (1) WO2023150689A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896570B (zh) * 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CN116096900A (zh) * 2020-05-13 2023-05-09 阿库斯股份有限公司 用于治疗gjb2相关听力损失的组合物和方法

Also Published As

Publication number Publication date
KR20240156606A (ko) 2024-10-30
MX2024009520A (es) 2024-09-11
EP4473005A2 (en) 2024-12-11
US20250127928A1 (en) 2025-04-24
WO2023150689A3 (en) 2023-11-16
CL2024002306A1 (es) 2024-12-27
JP2025506419A (ja) 2025-03-11
IL314705A (en) 2024-10-01
CA3250345A1 (en) 2023-08-10
WO2023150689A8 (en) 2023-10-12
EP4473005A4 (en) 2026-02-18
CO2024012057A2 (es) 2024-09-30
WO2023150689A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US12534739B2 (en) AAV1 vectors and uses thereof for treatment of otic indications
CA3159549A1 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
US20240309399A1 (en) Methods and compositions for administering otoferlin dual vector systems
US20240401079A1 (en) Stereocilin promoters and uses thereof
US20250127928A1 (en) Gjb2 regulatory elements and uses thereof
US20260034248A1 (en) Slc26a4 regulatory elements and uses thereof
CN118974264A (zh) Gjb2调控元件及其用途
WO2024073635A2 (en) Slc26a4 regulatory elements and uses thereof
CA3268952A1 (en) Slc26a4 regulatory elements and uses thereof
EP4713463A1 (en) Compositions and methods for treating gjb2-related hearing loss
EA053066B1 (ru) Промоторы стереоцилина и варианты их применения
CN118591631A (zh) 硬纤毛蛋白启动子及其用途